Cargando…

Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria

OBJECTIVE: The objective of this study was to determine the proportion of the Anambra State population that had been infected by the SARS-CoV-2 virus and developed antibodies before the second wave. METHODS: The WHO-recommended health facility-based cross-sectional approach was adapted for this surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Okpala, OgoChukwu Vincent, Dim, Cyril Chukwudi, Ugwu, Chukwuebuka Immanuel, Onyemaechi, Simeon, Uchebo, Obiageli, Chukwulobelu, Ugochukwu, Emembolu, Chuma, Okoye, Ben, Igboekwu, Chukwumuanya, Okoye, Uchenna Benedict, Dike, Nelly Chibuzor, Odumegwu, Anastasia Obiageli, Ideh, Christopher, Okoye, Ngozi Christiana, Okpala, Vincent Chinedu, Okoye, Peter Ikenna, Enike, Maryann Chinyere, Onyedikachi, Oluchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288214/
https://www.ncbi.nlm.nih.gov/pubmed/34293489
http://dx.doi.org/10.1016/j.ijid.2021.07.040
_version_ 1783724054990028800
author Okpala, OgoChukwu Vincent
Dim, Cyril Chukwudi
Ugwu, Chukwuebuka Immanuel
Onyemaechi, Simeon
Uchebo, Obiageli
Chukwulobelu, Ugochukwu
Emembolu, Chuma
Okoye, Ben
Igboekwu, Chukwumuanya
Okoye, Uchenna Benedict
Dike, Nelly Chibuzor
Odumegwu, Anastasia Obiageli
Ideh, Christopher
Okoye, Ngozi Christiana
Okpala, Vincent Chinedu
Okoye, Peter Ikenna
Enike, Maryann Chinyere
Onyedikachi, Oluchi
author_facet Okpala, OgoChukwu Vincent
Dim, Cyril Chukwudi
Ugwu, Chukwuebuka Immanuel
Onyemaechi, Simeon
Uchebo, Obiageli
Chukwulobelu, Ugochukwu
Emembolu, Chuma
Okoye, Ben
Igboekwu, Chukwumuanya
Okoye, Uchenna Benedict
Dike, Nelly Chibuzor
Odumegwu, Anastasia Obiageli
Ideh, Christopher
Okoye, Ngozi Christiana
Okpala, Vincent Chinedu
Okoye, Peter Ikenna
Enike, Maryann Chinyere
Onyedikachi, Oluchi
author_sort Okpala, OgoChukwu Vincent
collection PubMed
description OBJECTIVE: The objective of this study was to determine the proportion of the Anambra State population that had been infected by the SARS-CoV-2 virus and developed antibodies before the second wave. METHODS: The WHO-recommended health facility-based cross-sectional approach was adapted for this survey. Between 8(th) and 15(th) December 2020, 3142 participants across the 21 local government areas (LGAs) of the State, aged one year and over, attending randomly selected health facilities, were recruited. Demographic and symptom-related information were collected from the participants as well as whole peripheral blood, which was tested for SARS-CoV-2 IgG and IgM with rapid test kits. RESULTS: 425 participants tested positive for IgG only, 74 for IgM only, while 54 were positive for both IgG and IgM. Overall, 553 positives were recorded, giving a crude seroprevalence of 17(.)6% (95% CI = 16(.)26 – 18(.)98). It ranged widely from 31(.)9% (95% CI = 24(.)43 – 40(.)22) in Onitsha North LGA to 5(.)4% (95% CI = 2(.)19 – 10(.)78) in Awka north. Bayesian Adjustments yielded a state seroprevalence of 16(.)1%. CONCLUSION: One in six state residents had been infected by SARS-CoV-2 and developed antibodies before the second wave. All LGAs, age groups, sexes, and settlement types were affected by COVID-19. A large proportion of the population remained susceptible to SARS-CoV-2.
format Online
Article
Text
id pubmed-8288214
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-82882142021-07-20 Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria Okpala, OgoChukwu Vincent Dim, Cyril Chukwudi Ugwu, Chukwuebuka Immanuel Onyemaechi, Simeon Uchebo, Obiageli Chukwulobelu, Ugochukwu Emembolu, Chuma Okoye, Ben Igboekwu, Chukwumuanya Okoye, Uchenna Benedict Dike, Nelly Chibuzor Odumegwu, Anastasia Obiageli Ideh, Christopher Okoye, Ngozi Christiana Okpala, Vincent Chinedu Okoye, Peter Ikenna Enike, Maryann Chinyere Onyedikachi, Oluchi Int J Infect Dis Article OBJECTIVE: The objective of this study was to determine the proportion of the Anambra State population that had been infected by the SARS-CoV-2 virus and developed antibodies before the second wave. METHODS: The WHO-recommended health facility-based cross-sectional approach was adapted for this survey. Between 8(th) and 15(th) December 2020, 3142 participants across the 21 local government areas (LGAs) of the State, aged one year and over, attending randomly selected health facilities, were recruited. Demographic and symptom-related information were collected from the participants as well as whole peripheral blood, which was tested for SARS-CoV-2 IgG and IgM with rapid test kits. RESULTS: 425 participants tested positive for IgG only, 74 for IgM only, while 54 were positive for both IgG and IgM. Overall, 553 positives were recorded, giving a crude seroprevalence of 17(.)6% (95% CI = 16(.)26 – 18(.)98). It ranged widely from 31(.)9% (95% CI = 24(.)43 – 40(.)22) in Onitsha North LGA to 5(.)4% (95% CI = 2(.)19 – 10(.)78) in Awka north. Bayesian Adjustments yielded a state seroprevalence of 16(.)1%. CONCLUSION: One in six state residents had been infected by SARS-CoV-2 and developed antibodies before the second wave. All LGAs, age groups, sexes, and settlement types were affected by COVID-19. A large proportion of the population remained susceptible to SARS-CoV-2. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-19 /pmc/articles/PMC8288214/ /pubmed/34293489 http://dx.doi.org/10.1016/j.ijid.2021.07.040 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Okpala, OgoChukwu Vincent
Dim, Cyril Chukwudi
Ugwu, Chukwuebuka Immanuel
Onyemaechi, Simeon
Uchebo, Obiageli
Chukwulobelu, Ugochukwu
Emembolu, Chuma
Okoye, Ben
Igboekwu, Chukwumuanya
Okoye, Uchenna Benedict
Dike, Nelly Chibuzor
Odumegwu, Anastasia Obiageli
Ideh, Christopher
Okoye, Ngozi Christiana
Okpala, Vincent Chinedu
Okoye, Peter Ikenna
Enike, Maryann Chinyere
Onyedikachi, Oluchi
Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria
title Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria
title_full Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria
title_fullStr Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria
title_full_unstemmed Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria
title_short Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria
title_sort population seroprevalence of sars-cov-2 antibodies in anambra state, south-east, nigeria
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288214/
https://www.ncbi.nlm.nih.gov/pubmed/34293489
http://dx.doi.org/10.1016/j.ijid.2021.07.040
work_keys_str_mv AT okpalaogochukwuvincent populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT dimcyrilchukwudi populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT ugwuchukwuebukaimmanuel populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT onyemaechisimeon populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT ucheboobiageli populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT chukwulobeluugochukwu populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT ememboluchuma populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT okoyeben populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT igboekwuchukwumuanya populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT okoyeuchennabenedict populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT dikenellychibuzor populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT odumegwuanastasiaobiageli populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT idehchristopher populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT okoyengozichristiana populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT okpalavincentchinedu populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT okoyepeterikenna populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT enikemaryannchinyere populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria
AT onyedikachioluchi populationseroprevalenceofsarscov2antibodiesinanambrastatesoutheastnigeria